In the latest close session, Vertex Pharmaceuticals (VRTX) was down 1.2% at $449.52. This change lagged the S&P 500's 1.16% loss on the day. Meanwhile, the Dow experienced a drop of 0.47%, and the ...

So far, the company's commercialized drugs have delivered billions of dollars in revenue. For example, in the latest quarter, ...

The stock has climbed in the double-digits in recent years. Vertex Pharmaceuticals ( VRTX 1.53%) has proven itself to be an ...

Vertex Pharmaceuticals Incorporated's stock has shown resilience, recovering from dips and maintaining a strong long-term growth trajectory, driven by its robust CF franchise and new product approvals ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

MADISON, Miss., July 13, 2022 (GLOBE NEWSWIRE) -- The Vertex Company, a V2X company (NYSE: VVX), has begun work on an up to $850 million U.S. Navy contract after the award was upheld by U.S Government ...

Vertex has no competitors and can succeed in capturing over 50% of the Cystic Fibrosis market. The stock seems to be fairly valued. The company has a bright future and an excellent balance sheet. I ...

Vertex Pharmaceuticals presents clinical data demonstrating benefits of Casgevy in SCD and TDT patients aged 5+ at ASH ...

TEL AVIV, ISRAEL, Aug. 30, 2022 (GLOBE NEWSWIRE) -- The Vertex Company, a V2X company (NYSE: VVX), announces a brand-new technology for the proposed Tel Aviv congestion pricing zone. The Optical ...

Vertex Founder and CEO Wayne Smith selected Cooper to harness the company’s momentum and carefully articulate the Vertex ethos of quality and project execution to the marketplace.

Tax solutions provider Vertex announced its acquisition of Germany-based e-invoicing software specialist Ecosio. The terms of the acquisition include an upfront cash payment of $69 million as well as ...

Vertex is spending $41 million upfront in a collaboration with Mammoth Biosciences. The two companies will develop gene-editing therapies targeting two genetic diseases. This deal shouldn't diminish ...